Potential Novel Targets in Breast Cancer

被引:5
作者
Rameshwar, Pranela [1 ]
机构
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA
关键词
Breast cancer; mesenchymal stem cells; gap junction; cancer stem cells; bone marrow; MESENCHYMAL STEM-CELLS; PREPROTACHYKININ-I GENE; GAP-JUNCTION PROTEINS; PRE-METASTATIC NICHE; BONE-MARROW STROMA; CONNEXIN EXPRESSION; MAMMARY-GLAND; GROWTH; PHENOTYPE; TUMORS;
D O I
10.2174/138920109787315024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review focuses on the properties of different breast cancer cell subsets, including cancer stem cells (CSCs) and cancer progenitors. The premise is that an understanding of self-renewal, the effects of aging microenvironment on the behavior of cancer cell subsets will map the path of development from CSCs to progenitors. The basic characterization of different cancer cell subsets will lead to their signatures and open the field to novel methods of prognosis and diagnosis. The identification of cancer progenitors would allow scientists to modify the cells genetically for de-differention to CSCs. This will benefit the field to understand the method by which CSCs are developed. The review discusses a reductionist approach for identifying the CSCs and other subsets in bone marrow. An understanding of the mechanisms by which cancer cell subsets interact with other cells of the bone marrow could lead to an understanding of cancer behavior in bone marrow. A protective role of mesenchymal stem cells after the cancer cells enter the marrow is proposed as the first step in the cancer cells forming gap junctional intercellular communication with stromal cells close to the endosteum. It is possible that microRNAs could be shared between the cancer cells and stroma. The review recapitulates two stages of breast cancer: an early stage when the cancer cells enter bone marrow, perhaps prior to clinical detection and during the stage of heavy tumor burden when a subset of cancer cells survive and can resurge years after remission. This review argues for new approaches to identify breast cancer stem cells, and to understand how this population of cells interacts with the bone marrow microenvironment. In summary, the presented approach could lead to the development of new drug targets and approaches to treat breast cancer.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 73 条
[1]  
Alexandrova E, 2003, J BUON, V8, P133
[2]   Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype [J].
Balic, Marija ;
Lin, Henry ;
Young, Lillian ;
Hawes, Debra ;
Giuliano, Armando ;
McNamara, George ;
Datar, Ram H. ;
Cote, Richard J. .
CLINICAL CANCER RESEARCH, 2006, 12 (19) :5615-5621
[3]   CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles [J].
Beier, Dagmar ;
Hau, Peter ;
Proescholdt, Martin ;
Lohmeier, Annette ;
Wischhusen, Joerg ;
Oefner, Peter J. ;
Aigner, Ludwig ;
Brawanski, Alexander ;
Bogdahn, Ulrich ;
Beier, Christoph P. .
CANCER RESEARCH, 2007, 67 (09) :4010-4015
[4]   The role of pericytes in blood-vessel formation and maintenance [J].
Bergers, G ;
Song, S .
NEURO-ONCOLOGY, 2005, 7 (04) :452-464
[5]   Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness [J].
Beyth, S ;
Borovsky, Z ;
Mevorach, D ;
Liebergall, M ;
Gazit, Z ;
Aslan, H ;
Galun, E ;
Rachmilewitz, J .
BLOOD, 2005, 105 (05) :2214-2219
[6]   Bone marrow stromal stem cells: Nature, biology, and potential applications [J].
Bianco, P ;
Riminucci, M ;
Gronthos, S ;
Robey, PG .
STEM CELLS, 2001, 19 (03) :180-192
[7]   Symmetric division of cancer stem cells - a key mechanism in tumor growth that should be targeted in future therapeutic approaches [J].
Boman, B. M. ;
Wicha, M. S. ;
Fields, J. Z. ;
Runquist, O. A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (06) :893-898
[8]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[9]   Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients [J].
Braun, S ;
Kentenich, C ;
Janni, W ;
Hepp, F ;
de Waal, J ;
Willgeroth, F ;
Sommer, H ;
Pantel, K .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :80-86
[10]   A QUANTITATIVE ASSAY FOR NUMBER OF MURINE LYMPHOMA CELLS CAPABLE OF PROLIFERATION IN VIVO [J].
BRUCE, WR ;
VANDERGA.H .
NATURE, 1963, 199 (488) :79-&